We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

This study has been withdrawn prior to enrollment.
(Lack of enrollment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01272258
First Posted: January 7, 2011
Last Update Posted: February 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
CytoDyn, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: February 2017
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)